Navigation Links
Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results

BEIJING, July 25, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2014, after market close on Thursday, August 14, 2014 EDT. The Company will host a conference call prior to the market opening on Friday, August 15, 2014, at 8:00 a.m. EDT (Friday, August 15, 2014 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.

To access the conference call, please dial 1-877-407-9039 (USA) or 1-201-689-8470 (International).  A replay of the call will be available from 11 a.m. EDT on August 15, 2014, to August 29, 2014, at midnight. To access the replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (International) and reference the replay pin number 13587706.

A live audio webcast of the call will also be available on the Investor Relations section of the Company's website at A webcast replay will be available on the Company's website for 30 days following the call, beginning August 15, 2014.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps and canine rabies. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. Sinovac has filed a new drug application with the China Food & Drug Administration for its proprietary enterovirus 71 vaccine, having been proven effective in preventing hand, foot and mouth disease in infants and children during its Phase III trial. The company is currently developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides vaccine. pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company has exported select vaccines to Mongolia, Nepal, the Philippines and Mexico, and was recently granted a license to commercialize its hepatitis A vaccine in Chile. For more information, please visit the Company's website at .


Sinovac Biotech Ltd.
Helen Yang / Chris Lee
Tel: +86-10-8279-9659 / 9696
Fax: +86-10-6296-6910

ICR Inc.
Bill Zima
U.S: 1-646-308-1707

SOURCE Sinovac Biotech Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac to Participate in UBS Asia Healthcare CEO Summit in November 2013
2. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
3. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
4. Sinovac Announces Resignation of Chup Hung Mok from Board of Directors
5. Semler to Report Second Quarter 2014 Financial Results and Host Conference Call on July 25, 2014
6. Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
7. The Conference That Isnt: No Panels, No Keynote Speakers - At the NorTech Innovation UnConference, Attendees Are in Charge
8. MiMedx to Present at 32nd Annual J.P. Morgan Healthcare Conference
9. Halozyme Therapeutics To Present At The 32nd Annual J.P. Morgan Healthcare Conference
10. Generex Announces Selection of Antigen Express Technology for Keynote Presentation at 2014 TIDES Conference
11. AMRI CEO to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Post Your Comments:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... Amgen, will join the faculty of the University of North Carolina Kenan-Flagler ... of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s ...
(Date:6/24/2016)... -- Regular discussions on a range of subjects including policies, debt ... said Poloz. Speaking at a lecture to the ... pointed to the country,s inflation target, which is set by ... "In certain areas there needs to ... goals, why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
Breaking Biology News(10 mins):